PT  - JOURNAL ARTICLE
AU  - Phetsouphanh, Chansavath
AU  - Khoo, Weng Hua
AU  - Jackson, Katherine
AU  - Klemm, Vera
AU  - Howe, Annett
AU  - Aggarwal, Anupriya
AU  - Akerman, Anouschka
AU  - Milogiannakis, Vanessa
AU  - Stella, Alberto Ospina
AU  - Rouet, Romain
AU  - Schofield, Peter
AU  - Faulks, Megan L.
AU  - Law, Hannah
AU  - Danwilai, Thidarat
AU  - Starr, Mitchell
AU  - Munier, C. Mee Ling
AU  - Christ, Daniel
AU  - Singh, Mandeep
AU  - Croucher, Peter I
AU  - Brilot-Turville, Fabienne
AU  - Turville, Stuart
AU  - Phan, Tri Giang
AU  - Dore, Gregory J
AU  - Darley, David
AU  - Cunningham, Philip
AU  - Matthews, Gail V
AU  - Kelleher, Anthony D
AU  - Zaunders, John J
TI  - High titre neutralizing antibodies in response to SARS-CoV-2 infection require RBD-specific CD4 T cells that include proliferative memory cells
AID  - 10.1101/2022.07.22.22277947
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.07.22.22277947
4099  - http://medrxiv.org/content/early/2022/07/24/2022.07.22.22277947.short
4100  - http://medrxiv.org/content/early/2022/07/24/2022.07.22.22277947.full
AB  - Long-term immunity to SARS-CoV-2 infection, including neutralizing antibodies and T cell-mediated immunity, is required in a very large majority of the population in order to reduce ongoing disease burden. We have investigated the association between memory CD4 and CD8 T cells and levels of neutralizing antibodies in convalescent COVID-19 subjects. Higher titres of convalescent neutralizing antibodies were associated with significantly higher levels of RBD-specific CD4 T cells, including specific memory cells that proliferated vigorously in vitro. Conversely, up to half of convalescent individuals had low neutralizing antibody titres together with a lack of receptor binding domain (RBD)- specific memory CD4 T cells. These low antibody subjects had other, non-RBD, spike-specific CD4 T cells, but with more of an inhibitory Foxp3+ and CTLA-4+ cell phenotype, rather than the effector T- bet+, cytotoxic granzymes+ and perforin+ cells seen in high antibody subjects. Single cell transcriptomics of antigen-specific CD4+ T cells from high antibody subjects revealed heterogenous RBD-specific CD4+ T cells that comprised central memory, transitional memory and Tregs, as well as cytotoxic clusters containing diverse TCR repertoires, that were absent in individuals with low antibody levels. However, vaccination in low antibody convalescent individuals led to a slight but significant improvement in RBD-specific memory CD4 T cells and increased neutralizing antibody titres. Our results suggest that targeting CD4 T cell epitopes proximal to and within the RBD- region should be prioritized in booster vaccines.One Sentence Summary Individuals with low neutralising antibody titres may be at risk of SARS-CoV-2 re-infection due to a failure to generate a high quality CD4 T cell response specific for receptor binding domain (RBD), including memory CD4 T cells that proliferate in vitro in response to RBD, and which are also therefore an important target for vaccine design.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSt Vincents Clinic Foundation Grant Medical Research Future Fund Grant National Health and Medical Research Council (NHMRC) Program Grant ID1149990 (ADK) NHMRC Fellowship ID1155678 (TGP) UNSW Cellular Genomics Futures Institute Seed Funding (WHK) Mrs Janice Gibson and the Ernest Heine Family Foundation (PIC and TGP) Garvan Institute COVID Catalytic Grant (TGP) UNSW COVID-19 Rapid Response Research Initiative (TGP) Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ADAPT study was approved by the St Vincents Hospital Human Research Ethics Committee (2020/ETH00964) and is a registered trial (ACTRN12620000554965) ADAPT-C sub study was approved by the same committee (2020/ETH01429) All data were stored using REDCap electronic data capture tools. Unexposed healthy adult donors were recruited through St Vincents Hospital which was approved by St Vincents Hospital Human Research Ethics Committee (HREC/13/SVH/145 and HREC/10/SVH/130) All participants gave written informed consent. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors